Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:CNTA NASDAQ:RYTM NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$9.79+0.8%$9.88$7.48▼$22.05$1.47B1.322.41 million shs667,773 shsCNTACentessa Pharmaceuticals$39.660.0%$33.17$10.95▼$40.26$5.92B1.132.33 million shs272,136 shsRYTMRhythm Pharmaceuticals$94.36+2.2%$87.97$55.31▼$122.20$6.47B1.94782,788 shs390,962 shsTGTXTG Therapeutics$38.04+5.4%$32.24$25.28▼$41.24$5.82B1.682.04 million shs2.73 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+0.80%+1.08%-0.88%-11.59%-57.03%CNTACentessa Pharmaceuticals+0.25%+0.53%-0.05%+58.68%+192.34%RYTMRhythm Pharmaceuticals+12.83%+9.66%+6.98%-14.50%+43.32%TGTXTG Therapeutics+6.70%+4.40%+7.66%+23.97%-4.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$9.79+0.8%$9.88$7.48▼$22.05$1.47B1.322.41 million shs667,773 shsCNTACentessa Pharmaceuticals$39.660.0%$33.17$10.95▼$40.26$5.92B1.132.33 million shs272,136 shsRYTMRhythm Pharmaceuticals$94.36+2.2%$87.97$55.31▼$122.20$6.47B1.94782,788 shs390,962 shsTGTXTG Therapeutics$38.04+5.4%$32.24$25.28▼$41.24$5.82B1.682.04 million shs2.73 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+0.80%+1.08%-0.88%-11.59%-57.03%CNTACentessa Pharmaceuticals+0.25%+0.53%-0.05%+58.68%+192.34%RYTMRhythm Pharmaceuticals+12.83%+9.66%+6.98%-14.50%+43.32%TGTXTG Therapeutics+6.70%+4.40%+7.66%+23.97%-4.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 2.78Moderate Buy$22.47129.60% UpsideCNTACentessa Pharmaceuticals 2.21Hold$40.702.63% UpsideRYTMRhythm Pharmaceuticals 2.84Moderate Buy$131.1939.04% UpsideTGTXTG Therapeutics 2.57Moderate Buy$50.0031.45% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, CNTA, RYTM, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$143.00 ➝ $144.005/5/2026BHVNBiohaven Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$23.00 ➝ $22.005/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026RYTMRhythm Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$35.00 ➝ $42.004/13/2026BHVNBiohaven Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/13/2026CNTACentessa Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$38.004/2/2026BHVNBiohaven CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.004/2/2026CNTACentessa Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/ACNTACentessa Pharmaceuticals$15M394.52N/AN/A$3.92 per share10.12RYTMRhythm Pharmaceuticals$189.76M34.08N/AN/A$2.08 per share45.36TGTXTG Therapeutics$616.29M9.45$2.99 per share12.74$4.08 per share9.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$738.82M-$6.96N/AN/AN/AN/A-1,146.34%-137.71%5/11/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.47N/AN/AN/AN/A-50.66%-36.65%5/13/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.11N/AN/AN/A-103.57%-266.56%-45.01%N/ATGTXTG Therapeutics$447.18M$2.7713.7315.53N/A72.56%101.12%51.88%5/6/2026 (Estimated)Latest BHVN, CNTA, RYTM, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38N/AN/AN/AN/AN/A5/11/2026Q1 2026BHVNBiohaven-$0.86-$0.69+$0.17-$0.88$0.27 millionN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.17-$0.06$0.12$200.33 millionN/A5/5/2026Q1 2026CNTACentessa PharmaceuticalsN/A-$0.52N/A-$0.52N/AN/A5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A3/2/2026Q4 2025BHVNBiohaven-$1.22-$1.21+$0.01-$1.21$3.86 millionN/A2/26/2026Q4 2025RYTMRhythm Pharmaceuticals-$0.79-$0.73+$0.06-$0.73$56.16 million$57.25 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven4.593.183.18CNTACentessa Pharmaceuticals0.218.578.57RYTMRhythm PharmaceuticalsN/A4.414.16TGTXTG Therapeutics0.384.103.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%CNTACentessa Pharmaceuticals82.01%RYTMRhythm PharmaceuticalsN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven13.80%CNTACentessa Pharmaceuticals7.09%RYTMRhythm Pharmaceuticals6.10%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239150.42 million129.66 millionOptionableCNTACentessa Pharmaceuticals200149.23 million138.65 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.35 millionOptionableTGTXTG Therapeutics290153.09 million142.70 millionOptionableBHVN, CNTA, RYTM, and TGTX HeadlinesRecent News About These CompaniesTG Therapeutics (TGTX) Q1 Earnings Lag Estimates2 hours ago | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTX3 hours ago | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6 at 7:00 AM | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTXApril 30, 2026 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by AnalystsApril 30, 2026 | marketbeat.comFortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings GrowthApril 28, 2026 | zacks.comTG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings GrowthApril 27, 2026 | zacks.comTG Therapeutics (TGTX) to Release Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comM&T Bank Corp Buys Shares of 125,789 TG Therapeutics, Inc. $TGTXApril 27, 2026 | marketbeat.comTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American ...April 22, 2026 | caledonianrecord.comCTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingApril 22, 2026 | finance.yahoo.comQ1 EPS Estimates for TG Therapeutics Cut by HC WainwrightApril 22, 2026 | marketbeat.comHC Wainwright Forecasts Lower Earnings for TG TherapeuticsApril 21, 2026 | marketbeat.comA Look At TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumApril 19, 2026 | finance.yahoo.comTG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster OutlookApril 18, 2026 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo FinanceApril 17, 2026 | finance.yahoo.comTGTX Completes Enrollment in Phase III Study on Subcutaneous BriumviApril 16, 2026 | zacks.comTG Therapeutics, Inc.: TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIApril 15, 2026 | finanznachrichten.deTG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIApril 15, 2026 | globenewswire.comTG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting DownsideMarch 31, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, CNTA, RYTM, and TGTX Company DescriptionsBiohaven NYSE:BHVN$9.78 +0.08 (+0.77%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Centessa Pharmaceuticals NASDAQ:CNTA$39.66 -0.01 (-0.04%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Rhythm Pharmaceuticals NASDAQ:RYTM$94.36 +2.05 (+2.22%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.TG Therapeutics NASDAQ:TGTX$38.04 +1.94 (+5.37%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
